Skip to main content
Clinical Trials/NCT02100592
NCT02100592
Completed
Phase 1

Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study

Ospedale Generale Di Zona Moriggia-Pelascini0 sites8 target enrollmentOctober 2012
ConditionsBrain Injury

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Brain Injury
Sponsor
Ospedale Generale Di Zona Moriggia-Pelascini
Enrollment
8
Primary Endpoint
Adverse events during verticalization
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Severe brain injuries induce alteration of state of consciousness. These functional limitations can be significantly alleviated by treatment neurorehabilitation, particularly if this is established early. It has been shown that treatment of vertical integration in patients in a vegetative state or minimally conscious state can improve the level of supervision and positive influence on rehabilitation. Therefore, there are sufficient indications that anticipate the treatment of vertical integration, since the phase of hospitalization in ICUs, may improve the functional outcome of the patient.

Detailed Description

Early verticalization and stepping with the equipment Hocoma Erigo, during monitoring of vital parameters. The device Erigo is already CE marked and, for the purposes of the study, will be used in accordance with the intended use of the same mark (after-market clinical investigation).

Registry
clinicaltrials.gov
Start Date
October 2012
End Date
March 2014
Last Updated
12 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Ospedale Generale Di Zona Moriggia-Pelascini
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient / a severe acquired brain injury occurred 3 to 30 days prior to enrollment
  • Age between 18 and 75 years
  • Glasgow Coma Scale ≤ 8 at entrance in ICUs
  • Adequate respiratory exchange with PaO2/FiO2 ≥ 250
  • Absence of sedation increased

Exclusion Criteria

  • Major chest trauma with multiple rib fractures and / or pneumothorax
  • Presence of fractures, vascular lesions, skin lesions with loss of substance in the abdomen, pelvis or lower limb
  • Cardiovascular instability despite support with amines
  • Intracranial pressure (ICP)\> 25 mm / Hg
  • Cerebral Perfusion Pressure (PPC) \<60 mm / Hg
  • Severe kidney failure requiring replacement therapy
  • Decompensated liver disease
  • Hematocrit value of ≤ 30%
  • Body weight\> 135 kg or height\> 210 cm
  • Deep vein thrombosis

Outcomes

Primary Outcomes

Adverse events during verticalization

Time Frame: 21 days: from T1 (first session) to T15 (last session)

It is a composite outcome, assessing the occurence of at least one of the following conditions (component outcomes): Heart rate \<40 bpm or\> 150 bpm; Mean arterial pressure \<70 mmHg; Arterial oxygen saturation \<90%; Onset of ECG anomalies; Traumatic dislodgement of a device;

Secondary Outcomes

  • Changes of hemodynamic parameters(21 days: from T1 (first session) to T15 (last session))

Similar Trials